BPC-157 + Sermorelin Stack: Complete Protocol, Doses, and Timing

BPC-157 (a synthetic 15-amino-acid peptide, sometimes called Body Protection Compound-157) and Sermorelin acetate (a 29-amino-acid growth hormone-releasing hormone, or GHRH, analogue) are two different molecules acting through two different receptor systems. Sermorelin has a documented human clinical and regulatory history because it was studied as a diagnostic agent for pediatric growth hormone deficiency. BPC-157 has no equivalent human trial record; nearly everything known about it comes from animal studies.

The direct answer: there is a plausible pharmacologic rationale for combining them, because they act on non-overlapping pathways with no known pharmacokinetic interaction, but no published randomized controlled trial has tested the combination in humans, and neither peptide has FDA approval for the injury-repair or anti-aging uses this stack targets. Anyone considering this combination is using two agents largely outside their approved or well-studied context, and the protocol below should be treated as background information for a conversation with a prescriber, not as a dosing instruction to self-administer.

Disambiguation: what each substance is

• BPC-157. A synthetic pentadecapeptide modeled on a fragment of a protein found in gastric juice. It is not FDA-approved for any indication and is not currently included on the FDA's list of bulk substances nominated for use in 503A compounding, which affects whether a compounding pharmacy can legally prepare it. Evidence for its effects is preclinical, meaning rodent and cell-based studies, not human trials.
• Sermorelin acetate. A synthetic analogue of the first 29 amino acids of endogenous GHRH. An intravenous formulation (marketed historically as Geref Diagnostic) received FDA approval as a diagnostic test for growth hormone deficiency in children, under NDA 019764 (FDA drug approval database). That product has since been discontinued by its manufacturer. The subcutaneous Sermorelin used in adult "anti-aging" or recovery protocols today is a compounded preparation, not the approved diagnostic product, and its use for those purposes is off-label.

Both peptides are frequently sold as "research chemicals" outside any pharmacy or prescriber relationship. That distribution channel is separate from, and does not carry the quality assurance of, a licensed 503A or 503B compounding pharmacy.

Why practitioners pair them

The stated logic is that BPC-157 acts locally, on tendon, muscle, ligament, and gut tissue, largely through effects reported in animal studies on nitric oxide signaling and vascular growth factor pathways, while Sermorelin acts systemically by stimulating the pituitary to release the body's own growth hormone, which raises IGF-1 and is thought to support connective tissue and general recovery. Because the two act on different receptors, there is no known pharmacokinetic conflict between them. That absence of a known interaction is not the same as evidence that combining them produces a better outcome than either alone. No trial has tested that question.

This is the load-bearing paragraph on this page: BPC-157 and Sermorelin have no documented pharmacokinetic interaction and act through separate receptor systems, so combining them is mechanistically plausible, but the combination itself has not been studied in a randomized human trial as of mid-2025. Sermorelin's evidence base includes a prior FDA-approved diagnostic indication and published GHRH-analogue trial literature in adults; BPC-157's evidence base is limited to animal and cell studies, with no completed human dose-finding trial in the peer-reviewed literature. Readers should treat any specific healing-timeline or hormone-level claim attached to this stack as unverified until checked against the primary literature.

A note on the sources behind this rewrite

The version of this page previously in circulation attached specific PubMed identifiers to individual claims (percentages, milligram doses, exact IGF-1 changes, a verbatim guideline quotation). On review, those identifiers could not be confirmed to match the claims beside them, and several pointed to citation numbers reused for unrelated statements. Rather than repeat unverifiable numbers with a false appearance of precision, this revision describes the underlying evidence in general terms (for example, "a rodent tendon study reported..." rather than a specific journal and PMID) and flags where a reader or clinician should pull the primary paper before relying on a number. This is a more honest representation of what is actually known than a page full of confident-sounding but unverified citations.

What is reported about each peptide, described cautiously

BPC-157 (animal and cell data only). Rodent studies have reported that BPC-157 accelerates healing in models of tendon injury, muscle injury after corticosteroid exposure, and gastrointestinal mucosal damage from NSAIDs, with proposed mechanisms involving vascular endothelial growth factor (VEGF) upregulation, nitric oxide pathway activation, and effects on growth factor receptor signaling. No phase 1 human dose-finding trial has been published in the peer-reviewed literature as of this writing. Specific dose or percentage-improvement figures from any single study should be verified against the original paper before being used clinically or in patient counseling.

Sermorelin (human trial and regulatory data exist, but for a different formulation and dose than most current protocols). GHRH-analogue therapy has been studied in adults in randomized trials measuring IGF-1 change and body composition, generally showing an IGF-1 increase and modest favorable shifts in fat and lean mass over months of use. The diagnostic intravenous formulation that received FDA approval was tested in children for a different purpose (confirming growth hormone deficiency) and at different doses than the nightly subcutaneous regimens practitioners now use in adults. Adverse effects reported with GHRH-analogue therapy in trials have included injection-site reactions, flushing, headache, and water retention; exact incidence figures vary by study and should not be quoted as a single fixed percentage without checking the specific trial.

Evidence boundary: what is established, plausible, and unproven

• Established: BPC-157 and Sermorelin act on different receptor systems. Sermorelin's parent compound (GHRH) and diagnostic formulation have FDA approval history in a pediatric diagnostic context. BPC-157 has no FDA approval for any use and is not on FDA's approved compounding bulk-substance list.
• Plausible but unproven in humans: that BPC-157 accelerates tendon, muscle, or ligament healing in people the way it does in rodents; that combining BPC-157 with Sermorelin produces faster or more complete recovery than either agent alone; that the combination has meaningful mood or cognitive benefits.
• Not established: any specific numeric dose, injection schedule, or cycle length for the combination backed by a human trial; any claim that the stack is free of long-term risk; any claim that compounded, non-pharmacy-grade peptide products meet the purity or sterility standards of an FDA-approved injectable drug.

Dosing information reported in practitioner and compounding literature (not a prescription)

The following reflects patterns described in compounding-pharmacy and practitioner materials, not an FDA label and not an individualized recommendation. Actual dosing, if a clinician decides this is appropriate for a specific patient, should be set by that clinician based on the patient's history, labs, and goals.

• BPC-157 is commonly discussed in ranges of roughly 250 to 500 mcg per subcutaneous or intramuscular injection, once or twice daily, with an oral capsule form sometimes used for gut-focused indications; oral systemic absorption is considered limited because peptides are broken down in digestion.
• Sermorelin is commonly discussed in ranges of roughly 100 to 300 mcg subcutaneously at night, timed before sleep to coincide with the body's natural overnight growth hormone pulse, with dose increases over several weeks.
• Practitioner materials often describe running Sermorelin in cycles of around 8 to 12 weeks followed by an off-period, based on the idea that continuous GHRH-receptor stimulation could downregulate receptor sensitivity, though the ideal cycle length for that purpose has not been established in a controlled trial.

None of this substitutes for an individualized plan from a prescriber who has reviewed the patient's history, current medications, and lab results.

Safety, contraindications, and when to stop and seek care

Contraindications that should stop this conversation before it starts:

• Active or suspected malignancy. Growth hormone and IGF-1 signaling can support cell proliferation, which is why GH-axis therapies are generally avoided in patients with active cancer. BPC-157's VEGF-related mechanism raises a similar theoretical concern about tumor blood supply, though this has not been tested clinically.
• Pregnancy or breastfeeding.
• Pediatric use outside a specialist endocrinology relationship; Sermorelin's only FDA-approved use was a pediatric diagnostic test administered under medical supervision, not a self-administered nightly regimen.

Reasons to contact a prescriber promptly during use: new or worsening headache with visual changes, unexplained rapid swelling, signs of an allergic reaction (hives, facial or throat swelling, difficulty breathing), chest pain, or any new lump or unexplained weight change. These warrant urgent evaluation rather than waiting for a scheduled follow-up.

Drug interaction note: no pharmacokinetic drug-drug interaction data exists for BPC-157. Growth hormone stimulation from Sermorelin can improve insulin sensitivity over time, which means patients on insulin or sulfonylureas should discuss glucose monitoring with their prescriber before starting.

Clinician-conversation and monitoring framework

This framework is intended to guide discussions between patients and their healthcare provider about BPC-157, not to replace such conversations. It distinguishes between information that can be cross-referenced with product labeling or clinical guidelines and considerations that demand personalized medical assessment.

Before starting, confirm with the prescriber:

1. Diagnosis and goal: is this being used for a specific injury, general recovery, or another goal? The answer changes what "success" and "stop" look like.
2. Cancer screening status appropriate for age and risk, given the theoretical proliferative signal from both agents.
3. Baseline labs: IGF-1, fasting glucose or HbA1c, a metabolic panel, and thyroid studies (TSH, free T4), since growth hormone activity interacts with thyroid hormone handling.
4. Source verification: does the compounding pharmacy hold a current 503A or 503B registration, and is there a certificate of analysis for the specific batch (identity, purity, endotoxin testing)? A prescriber or pharmacist can confirm what a valid certificate should show.
5. Explicit discussion that this is an off-label, compounded, and for BPC-157, non-FDA-approved use, with no long-term human safety data for the combination.

Checkpoints once started (timing set by the prescriber, not a fixed rule):

• Early check (roughly 2 to 4 weeks in): tolerability review, injection-site check, blood pressure if clinically relevant, and a symptom check for headache, joint pain, or swelling.
• Mid-cycle check (commonly discussed around week 6): repeat IGF-1 and glucose, symptom review.
• End-of-cycle check (commonly discussed around week 12): repeat IGF-1, glucose, and metabolic panel; reassess whether the original goal has been met.
• Post-cycle check (several weeks after stopping Sermorelin): confirm IGF-1 has returned toward baseline before considering another cycle.

Stop or escalate if:

• IGF-1 rises above the age-adjusted reference range at any check, which is a signal to pause and reassess dosing rather than continue.
• Any new mass, unexplained lump, or cancer-concerning symptom appears.
• Glucose control worsens meaningfully in a patient on diabetes medication.
• A significant allergic or injection-site reaction occurs.

What sits outside label guidance and requires individual judgment: the exact dose, the cycle length, whether to combine the two agents at all, and how to interpret a borderline lab value in a specific patient are all site- and clinician-level judgment calls, not things this article or any general reference can settle. A prescriber weighing these should document that the patient understands the investigational nature of the combination.

Regulatory and sourcing status (checked as of 2025)

Sermorelin's only FDA-approved form was an intravenous diagnostic product that has since been discontinued by its manufacturer; the subcutaneous Sermorelin used in current protocols is a compounded preparation made under a prescriber's order at a 503A pharmacy or produced at scale by a 503B outsourcing facility (FDA compounding laws and policies). BPC-157 is not FDA-approved and is not currently on the FDA list of bulk substances nominated for 503A compounding, which is a relevant factor in whether a legitimate compounding pharmacy can prepare it under that pathway. Compounded drugs are not FDA-approved products and are not evaluated for safety and effectiveness the way an approved drug is; quality depends heavily on the individual pharmacy's compliance with current good manufacturing practice standards (FDA cGMP resources). Regulatory status can change; anyone acting on this information should confirm current status before use rather than relying on a static article.

Peptides sold directly to consumers as "research chemicals," without a prescription or pharmacy involvement, sit outside this compounding framework entirely and carry no assurance of purity, sterility, or accurate labeling.

Honest gaps this page cannot fill

No randomized trial has tested BPC-157 with Sermorelin together in humans. No trial has established an optimal dose, cycle length, or injection timing for either agent for the injury-recovery or general-wellness goals this stack targets in adults. Reported side-effect rates, healing timelines, and hormone-level changes in the underlying animal and single-agent human literature vary by study and should be checked against the original paper rather than treated as fixed numbers. A clinician who is asked about this stack should be transparent with the patient about all of this rather than presenting a confident protocol as though it were guideline-backed.

References

• FDA drug approval database, Geref Diagnostic (Sermorelin Acetate), NDA 019764: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019764
• FDA, Compounding Laws and Policies: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
• FDA, Current Good Manufacturing Practice (cGMP) Regulations: https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations

The prior version of this article cited specific PubMed articles (PMIDs) for individual mechanistic and clinical claims about BPC-157 and GHRH-analogue trials. Those identifiers could not be verified as matching the claims presented and are not repeated here. A qualified reviewer with database access should identify and cite the correct primary papers for the animal-study and human-trial claims described in general terms above before this page is published.